Technology
Health
Medical
Cytosorbents
$7.559876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$7.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.45 (-5.63%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Cytosorbents and other stocks, options, ETFs, and crypto commission-free!
About
CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. Read More The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
Employees
125
Headquarters
Monmouth Junction, New Jersey
Founded
2002
Market Cap
239.89M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
232.47K
High Today
$8.02
Low Today
$7.52
Open Price
$7.93
Volume
66.71K
52 Week High
$14.95
52 Week Low
$6.67
Collections
Technology
Health
Medical
US
North America
News
The Motley FoolMar 7
Cytosorbents Corp (CTSO) Q4 2018 Earnings Conference Call Transcript
Cytosorbents Corp (NASDAQ:CTSO) Q4 2018 Earnings Conference Call , 4:45 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, and welcome to the CytoSorbents 2018 Financial and Operating Results Conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the Company's request. At this time, I'd like...
Markets InsiderMar 7
CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018
MONMOUTH JUNCTION, N.J., March 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, achieves record total revenue, CytoSorb® sales, and product gross margins in 2018. 2018 Financial Highlights: Full year 2018 total revenue was $22.5 million , including both product sales and grant income, a 49% increase fro...
Price Paid on Robinhood
3% Lower
Right Now
52 Week Low
$6.67
Average Price Paid
$7.79
52 Week High
$14.95
Earnings
-$0.19
-$0.14
-$0.09
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, After Hours